MedTrace Logo

Ixovex-1 Single Agent and Combination Therapy

NCT06549946 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-01-30

No results posted yet for this study

Summary

This is an open-label, dose de-escalating, non-randomised, multi-centre phase I/II study to determine safety and efficacy of the oncolytic virus, Ixovex-1 administered by intratumoural (IT) injection. This will be assessed in patients with palpable locally advanced, unresectable, or metastatic tumours, for whom all approved therapeutic options have been exhausted, are not available, are unlikely to have significant clinical benefit, or are declined by the patient.

Conditions

Interventions

BIOLOGICAL

Ixovex-1

Ixovex-1 is a novel oncolytic human adenovirus serotype 5.

BIOLOGICAL

Pembrolizumab

Humanised antibody

Sponsors & Collaborators

  • IQVIA Biotech

    collaborator INDUSTRY

  • Psivac Ltd

    lead INDUSTRY

Principal Investigators

  • Kevin Harrington · The Royal Marsden

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-17
Primary Completion
2027-01-30
Completion
2027-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06549946 on ClinicalTrials.gov